Edwin C K Tan1, Renuka Visvanathan2,3, Sarah N Hilmer4,5, Tina Emery6, Leonie Robson6, Agnes I Vitry7, Jessica M Hughes8, Mary J Jones8, Sarah Moawad8, Jenni Ilomäki8, Tara Quirke9, J Simon Bell10,11,12. 1. Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Melbourne, VIC, 3052, Australia. edwin.tan@monash.edu. 2. Discipline of Medicine, University of Adelaide, Adelaide, Australia. 3. Aged and Extended Care Services, The Queen Elizabeth Hospital and Adelaide Geriatrics Training and Research with Aged Care (GTRAC) Centre, School of Medicine, University of Adelaide, Adelaide, Australia. 4. Department of Clinical Pharmacology and Aged Care, Kolling Institute of Medical Research, Sydney Medical School, Royal North Shore Hospital, The University of Sydney, Sydney, Australia. 5. NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, Australia. 6. Resthaven Incorporated, Adelaide, Australia. 7. Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia. 8. Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Melbourne, VIC, 3052, Australia. 9. Consumer Dementia Research Network, Alzheimer's Australia, Scullin, Australia. 10. Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Melbourne, VIC, 3052, Australia. simon.bell2@monash.edu. 11. NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, Australia. simon.bell2@monash.edu. 12. Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia. simon.bell2@monash.edu.
Abstract
BACKGROUND: Managing pain in residents of residential aged care facilities (RACFs) is challenging, especially for people with dementia. Clinicians must weigh the benefits of analgesic use against the potential for adverse events, particularly daytime sleepiness. OBJECTIVES: The aim was to investigate the association between analgesic use and daytime sleepiness in residents with and without dementia in RACFs. METHODS: This was a cross-sectional study of 383 permanent residents from six low-level and high-level RACFs in South Australia. Main measures included analgesic use in the previous 24 h, analgesic load and self-reported daytime sleepiness. Covariates included relevant comorbidities (insomnia, depression, painful conditions), Charlson's Comorbidity Index, sedative load, self-reported and clinician-observed pain and dementia severity. Logistic regression was used to compute odds ratios (ORs) and confidence intervals (CIs) for the association between analgesic use and daytime sleepiness. RESULTS: Analgesics were used by 288 residents (75.2%) in the previous 24 h. These included paracetamol (n = 264, 68.9%), opioids (n = 110, 28.7%) and oral NSAIDs (n = 14, 3.7%). Overall, 116 (30.3%) residents were categorized as having daytime sleepiness. Of those with dementia, 77 (45.6%) were categorized as having daytime sleepiness. Opioid use in the previous 24 h was not associated with daytime sleepiness in unadjusted or adjusted analyses. Paracetamol use was positively associated with daytime sleepiness (OR 2.31; 95% CI 1.20-4.42). CONCLUSION: Although daytime sleepiness occurred in a large number of residents, especially those with dementia, this sleepiness was not necessarily associated with use of opioids. The risk of opioid-induced sedation may have been managed by strategies including preferential prescribing of paracetamol to residents at risk of sleepiness, opioid discontinuation in residents who experienced sleepiness, and use of low doses of opioids.
BACKGROUND: Managing pain in residents of residential aged care facilities (RACFs) is challenging, especially for people with dementia. Clinicians must weigh the benefits of analgesic use against the potential for adverse events, particularly daytime sleepiness. OBJECTIVES: The aim was to investigate the association between analgesic use and daytime sleepiness in residents with and without dementia in RACFs. METHODS: This was a cross-sectional study of 383 permanent residents from six low-level and high-level RACFs in South Australia. Main measures included analgesic use in the previous 24 h, analgesic load and self-reported daytime sleepiness. Covariates included relevant comorbidities (insomnia, depression, painful conditions), Charlson's Comorbidity Index, sedative load, self-reported and clinician-observed pain and dementia severity. Logistic regression was used to compute odds ratios (ORs) and confidence intervals (CIs) for the association between analgesic use and daytime sleepiness. RESULTS: Analgesics were used by 288 residents (75.2%) in the previous 24 h. These included paracetamol (n = 264, 68.9%), opioids (n = 110, 28.7%) and oral NSAIDs (n = 14, 3.7%). Overall, 116 (30.3%) residents were categorized as having daytime sleepiness. Of those with dementia, 77 (45.6%) were categorized as having daytime sleepiness. Opioid use in the previous 24 h was not associated with daytime sleepiness in unadjusted or adjusted analyses. Paracetamol use was positively associated with daytime sleepiness (OR 2.31; 95% CI 1.20-4.42). CONCLUSION: Although daytime sleepiness occurred in a large number of residents, especially those with dementia, this sleepiness was not necessarily associated with use of opioids. The risk of opioid-induced sedation may have been managed by strategies including preferential prescribing of paracetamol to residents at risk of sleepiness, opioid discontinuation in residents who experienced sleepiness, and use of low doses of opioids.
Authors: Albert Lukas; Benjamin Mayer; Daniela Fialová; Eva Topinkova; Jacob Gindin; Graziano Onder; Roberto Bernabei; Thorsten Nikolaus; Michael D Denkinger Journal: J Am Med Dir Assoc Date: 2013-06-06 Impact factor: 4.669
Authors: Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski Journal: J Pain Date: 2009-02 Impact factor: 5.820
Authors: Amie C Hayley; Lana J Williams; Michael Berk; Gerard A Kennedy; Felice N Jacka; Julie A Pasco Journal: Aust N Z J Psychiatry Date: 2013-05-15 Impact factor: 5.744
Authors: Henna Hiltunen; Edwin C K Tan; Jenni Ilomäki; Sarah N Hilmer; Renuka Visvanathan; Tina Emery; Leonie Robson; Mary J Jones; Sirpa Hartikainen; J Simon Bell Journal: Ther Adv Drug Saf Date: 2016-04-01
Authors: Samanta Lalic; Kris M Jamsen; Barbara C Wimmer; Edwin C K Tan; Sarah N Hilmer; Leonie Robson; Tina Emery; J Simon Bell Journal: Eur J Clin Pharmacol Date: 2016-06-02 Impact factor: 2.953
Authors: Francesca L La Frenais; Rachel Bedder; Victoria Vickerstaff; Patrick Stone; Elizabeth L Sampson Journal: J Am Geriatr Soc Date: 2017-12-23 Impact factor: 5.562
Authors: Natali Jokanovic; Kris M Jamsen; Edwin C K Tan; Michael J Dooley; Carl M Kirkpatrick; J Simon Bell Journal: Drugs Real World Outcomes Date: 2017-12